Co-investor in Ucello Therapeutics' $25M Series A led by Matrix Partners China.
Ucello Therapeutics is focused on the research, development, production, and operation of universal CAR-T cell therapy products, particularly utilizing umbilical cord blood-derived T cells
Ucello Therapeutics is focused on the research, development, production, and operation of universal CAR-T cell therapy products, particularly utilizing umbilical cord blood-derived T cells. Their lead product, UC101, targets acute B-lymphoblastic leukemia and aims to enhance the efficacy of CAR-T therapies.